VP16 serine 375 is a critical determinant of herpes simplex virus exit from latency in vivo

Ace CI, McKee TA et al (1989) Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression. J Virol 63(5):2260–2269 Ecob-Prince MS, Preston CM et al (1993a) Neurons containing latency-associated transcripts are numerous and widespread in dorsal root ganglia following footpad inoculation of mice with herpes simplex virus type 1 mutant in1814. J Gen Virol 74(Pt 6):985–994 Ecob-Prince MS, Rixon FJ et al (1993b) Reactivation in vivo and in vitro of herpes simplex virus from mouse dorsal root ganglia which contain different levels of latency-associated transcripts. J Gen Virol 74(Pt 6):995–1002 Glynn JR, Biraro S et al (2009) Herpes simplex virus type 2: a key role in HIV incidence. AIDS 23(12):1595–1598 Harris RA, Preston CM (1991) Establishment of latency in vitro by the herpes simplex virus type 1 mutant in1814. J Gen Virol 72(Pt 4):907–913 Honess RW, Roizman B (1974) Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 14(1):8–19 Itzhaki RF, Wozniak MA (2008) Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J Alzheimers Dis 13(4):393–405 Knipe D (2007) Fields virology. Lippincott Williams & Wilkins, Philadelphia Lam Q, Smibert CA et al (1996) Herpes simplex virus VP16 rescues viral mRNA from destruction by the virion host shutoff function. EMBO J 15(10):2575–2581 McFarlane M, Daksis JI et al (1992) Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expression in the absence of trans-induction by Vmw65. J Gen Virol 73(Pt 2):285–292 Mossman KL, Sherburne R et al (2000) Evidence that herpes simplex virus VP16 is required for viral egress downstream of the initial envelopment event. J Virol 74(14):6287–6299 Mukamal KJ, Kronmal RA et al (2004) Traditional and novel risk factors in older adults: cardiovascular risk assessment late in life. Am J Geriatr Cardiol 13(2):69–80 O'Reilly D, Hanscombe O et al (1997) A single serine residue at position 375 of VP16 is critical for complex assembly with Oct-1 and HCF and is a target of phosphorylation by casein kinase II. EMBO J 16(9):2420–2430 Ottosen S, Herrera FJ et al (2006) Phosphorylation of the VP16 transcriptional activator protein during herpes simplex virus infection and mutational analysis of putative phosphorylation sites. Virology 345(2):468–481 Pepose JS, Keadle TL et al (2006) Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol 141(3):547–557 Preston CM, McFarlane M (1998) Cytodifferentiating agents affect the replication of herpes simplex virus type 1 in the absence of functional VP16. Virology 249(2):418–426 Proenca JT, HM Coleman et al. (2011) An investigation of HSV promoter activity compatible with latency establishment reveals VP16 independent activation of HSV immediate early promoters in sensory neurones. J Gen Virol 92(11):2575–2585 Roberts S (2009) Herpes simplex virus: incidence of neonatal herpes simplex virus, maternal screening, management during pregnancy, and HIV. Curr Opin Obstet Gynecol 21(2):124–130 Roizman B, Gu H et al (2005) The first 30 minutes in the life of a virus: unREST in the nucleus. Cell Cycle 4(8):1019–1021 Sawtell NM (1997) Comprehensive quantification of herpes simplex virus latency at the single-cell level. J Virol 71(7):5423–5431 Sawtell NM (1998) The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 72(8):6888–6892 Sawtell NM (2003) Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation. J Virol 77(7):4127–4138 Sawtell NM (2005) Detection and quantification of the rare latently infected cell undergoing herpes simplex virus transcriptional activation in the nervous system in vivo. Methods Mol Biol 292:57–72 Sawtell NM, Thompson RL (1992) Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency. J Virol 66(4):2157–2169 Sawtell NM, Thompson RL et al (2006) Herpes simplex virus DNA synthesis is not a decisive regulatory event in the initiation of lytic viral protein expression in neurons in vivo during primary infection or reactivation from latency. J Virol 80(1):38–50 Sears AE, Hukkanen V et al (1991) Expression of the herpes simplex virus 1 alpha transinducing factor (VP16) does not induce reactivation of latent virus or prevent the establishment of latency in mice. J Virol 65(6):2929–2935 Smiley JR, Duncan J (1997) Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of the in1814 linker insertion mutation. J Virol 71(8):6191–6193 Steiner I, Spivack JG et al (1990) A herpes simplex virus type 1 mutant containing a nontransinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 64(4):1630–1638 Stone MJ, Hawkins CP (2007) A medical overview of encephalitis. Neuropsychol Rehabil 17(4–5):429–449 Sun Y, Pei W et al (2005) An association of herpes simplex virus type 1 infection with type 2 diabetes. Diabetes Care 28(2):435–436 Tal-Singer R, Pichyangkura R et al (1999) The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems. Virology 259(1):20–33 Thompson RL, Preston CM et al (2009) De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathog 5(3):e1000352 Thompson RL, Sawtell NM (2006) Evidence that the herpes simplex virus type 1 ICP0 protein does not initiate reactivation from latency in vivo. J Virol 80(22):10919–10930 Valyi-Nagy T, Deshmane SL et al (1991) Investigation of herpes simplex virus type 1 (HSV-1) gene expression and DNA synthesis during the establishment of latent infection by an HSV-1 mutant, in1814, that does not replicate in mouse trigeminal ganglia. J Gen Virol 72(Pt 3):641–649 Visser, M. R. and G. M. Vercellotti (1993) Herpes simplex virus and atherosclerosis. Eur Heart J 14 Suppl K: 39–42. Wysocka J, Herr W (2003) The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci 28(6):294–304